-

12:10:28 PM

Latest OCGN Stock Market News

OCGN - OCGN

06/18/21 4:12 PM

Nasdaq : OCGN

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

RHEA-AI

very positive

06/16/21 7:30 AM

Nasdaq : OCGN

Ocugen Inc. Set to Join Russell 3000® Index

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join

RHEA-AI

neutral

06/15/21 7:30 AM

Nasdaq : OCGN

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save

RHEA-AI

neutral

06/10/21 7:35 AM

Nasdaq : OCGN

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will

RHEA-AI

neutral

06/10/21 7:30 AM

Nasdaq : OCGN

Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate

Ocugen, Inc. (NASDAQ: OCGN) (Company), a

RHEA-AI

neutral

06/03/21 7:30 AM

Nasdaq : OCGN

Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering,

RHEA-AI

very positive

05/26/21 8:06 PM

Nasdaq : OCGN

Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and

RHEA-AI

neutral

05/07/21 7:30 AM

Nasdaq : OCGN

Ocugen Provides Business Update and First Quarter 2021 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization) Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency Use Authorization application for COVAXIN $100.0 million

RHEA-AI

neutral

05/06/21 7:30 AM

Nasdaq : OCGN

Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

OCU200, a transferrin-tumstatin fusion protein, demonstrates potential to treat DME, DR, and Wet-AMD OCU200 reduced neovascularization and damage to retina and demonstrated comparable/slightly improved activity to aflibercept in an animal disease model MALVERN, Pa., May 06, 2021

RHEA-AI

neutral

05/03/21 4:35 PM

Nasdaq : OCGN

Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a

RHEA-AI

neutral